Analysis of cytokine gene polymorphisms in patients with chronic diffusional liver diseases in Perm krai

Aim. To estimate the concentration of tumor necrosis factor-alpha (TNF-α), interleukin-6 (interleukin, IL-6), vascular endothelial growth factor (VEGF) in blood serum and to analyze the polymorphism of TNF-α cytokine genes in region 308G / A (rs1800629), IL-6 in region 174G / C (rs1800795) and VEGFA in region 634G / C (rs2010963) in patients with chronic diffuse liver diseases (CDLD) living in the Perm region. Materials and methods. In 193 patients with CDLD and 90 healthy donors, the concentration of cytokines in the blood serum was studied by ELISA and the analysis of cytokine gene polymorphism by PCR was performed. Results. In patients with CDLD, the concentration of pro-inflammatory cytokines TNF-α, IL-6 and the level of VEGF in the blood serum were significantly higher than in the control (p <0.001, respectively), while the maximum level of inflammation markers was noted in liver cirrhosis, and VEGF production - in chronic hepatitis C. Comparative analysis of single nucleotide polymorphisms of cytokine genes showed significant differences in the occurrence of the GA and AA genotypes of the TNF-α gene (G-308A), the carriage of the CG variant of the IL-6 gene (C-174G), as well as the C allele and CC homozygote for marker VEGF (G-634C), which in the population of patients with CDLD in the Perm region were recorded significantly more often than in the cohort of donors, which allows us to consider them as genetic markers of the risk of developing CDLD. Conclusion. An increase in the concentration of pathogenetically significant cytokines TNF-α, IL-6 and VEGF in liver diseases can develop against the background of gene polymorphisms of these molecules. Genetic markers can be used to assess the risk of developing and progression of CDLD.

chronic diffuse liver diseases, tumor necrosis factor-α, interleukin-6, vasculoendothelial growth factor, gene polymorphism

1. Kuz’mina Yu.S., Zhmurov V. A., Mishchenko T. A., et al. Clinical and laboratory factors of an unfavorable prognosis of the disease in patients with liver cirrhosis. Medical science and education of the Urals. 2020; 3(103): 12-16. (In Russ.) doi: 10 .36361/1814-8999-2020-21-3-12-16 @@Кузьмина Ю. С., Жмуров В. А., Мищенко Т. А. и соавт. Клинико-лабораторные факторы неблагоприятного прогноза заболевания у пациентов с циррозом печени. Медицинская наука и образование Урала. -2020. - № 3(103). -С.12-16

2. Mekhtiev S.N., Stepanenko V. V., Zinov’eva E.N., Mekhtieva O. A. Modern concepts of liver fibrosis and methods of its correction. Farmateka.2014; 6:80-87. (In Russ.) @@Мехтиев С. Н., Степаненко В. В., Зиновьева Е. Н., Мехтиева О. А. Современные представления о фиброзе печени и методах его коррекции. Фарматека. -2014. -№ 6. -С.80-87

3. Kiseleva Ya.V., Zharikov Yu.O., Maslennikov R. V., et al. Molecular factors associated with regression of liver fibrosis of alcoholic etiology. Terapevticheskii arkhiv. 2021;(2):204-208. (In Russ) doi: 10.26442/00403660.2021.02.200617 @@Киселева Я. В., Жариков Ю. О., Масленников Р. В. и соавт. Молекулярные факторы, ассоциированные с регрессом фиброза печени алкогольной этиологии. Терапевтический архив. -2021. -№ 2. -С.204-208

4. Lee Y.A., Wallace M. C., Friedman S. L. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830-41. doi: 10.1136/gutjnl-2014-306842

5. Park S., Kim J. W., Kim J. H., et al. Differential Roles of Angiogenesis in the Induction of Fibrogenesis and the Resolution of Fibrosis in Liver. Biol Pharm Bull. 2015;38(7):980-5. doi: 10.1248/bpb.b15-00325

6. Bodienkova G.M., Titova Zh. V. The role of polymorphism and expression of individual cytokine genes in the formation of pathology. Advances in current natural sciences. 2015; 1: 616-620. (In Russ.) @@Бодиенкова Г. М., Титова Ж. В. Роль полиморфизма и экспрессии отдельных генов цитокинов в формировании патологии. Успехи современного естествознания. -2015. -№ 1. -С.616-620

7. Liu Y., Kwon J., Popov Y., et al. Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice. Gastroenterology. 2014;146(5):1339-50.e1. doi:10.1053/j.gastro.2014.01.061

8. Dirchwolf М., Podhorzer А., Morino М., et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes ac-cording to cirrhosis severity. J. Cytokine. 2016;77:14-25. doi: 10.1016/j.cyto.2015.10.006

9. Martmez-Esparza M., Tristan-Manzano М., Ruiz-Alcaraz A.J., Garda-Penarrubia Р. Inflammatory status in human hepatic cirrhosis. World J. Gastroenterol. 2015;21(41): 11522-11541. doi: 10.3748/wjg.v21.i41.11522

10. Skuratov A.G., Lyzikov A. N., Voropaev E. V., Osipkina O. V.Interleukin-6 as an indicator of severity of liver cirrhosis and portal hypertension. Health and Ecology Issues. 2016;(4):110-114. (In Russ.) doi: 10.51523/2708-6011.2016-13-4-24 @@Скуратов А. Г., Лызиков А. Н., Воропаев Е. В., Осипкина О. В. Уровень интерлейкина-6 как показатель тяжести цирроза печени и портальной гипертензии. Проблемы здоровья и экологии. -2016. - № 4 (50). - С.110-114

11. Ruhi K., Quaiser S., Haque S. F., Ahmad A. TNF-α is an inflammatory marker of Cardiovascular risks in Non-alcoholic fatty liver disease. Journal of Clinical and Diagnostic Research. 2011;5(6):1237-1240

12. Abiru S., Migita K., Maeda Y., Daikoku M., et al. Serum cytokine and soluble cytokine receptor levels in patients with nonalcoholic steatohepatitis. Liver Int. 2006; 26(1):39-45. doi: 10.1111/j.1478-3231.2005.01191.x

13. Pivtorak E. V. Endothelial dysfunction in patients with non-alcoholic fatty liver disease. Eksp Klin Gastroenterol. 2014;(2):63. (In Russ.) @@Пивторак Е. В. Нарушения функции эндотелия у больных неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. -2014. -№ 2. -С.63

14. Zhou Y.J., Li Y. Y., Nie Y. Q., et al. Influence of polygenetic polymorphisms on the susceptibility to nonalcoholic fatty liver disease of Chinese people. J. Gastroenterol. Hepatol. 2010; 4 (25): 772-777. doi: 10.1111/j.1440-1746.2009.06144.x

15. Nikolaeva L.I., Kolotvin A. V., Samokhodskaya L. M., et al. Analysis of the influence of genetic factors of the hepatitis C virus and gene polymorphism of infected people on the development of liver fibrosis. Epidemiology and Infectious Diseases. Current Items. 2012; 5: 7-13. (in Russ.) @@Николаева Л. И., Колотвин А. В., Самоходская Л. М. и др. Анализ влияния генетических факторов вируса гепатита Сиполиморфизма генов инфицированных людей на развитие фиброза печени. Эпидемиология и инфекционные болезни. -2012. -№ 5. -С.7-13

16. Jeng J.E., Tsai J. F., Chuang L. Y., et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia. 2007; 9 (11): 987-992. doi: 10.1593/neo.07781

17. Meenagh A., Williams F., Ross O. A., et al. Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. Hum Immunol. 2002; 63: 1055-1061. doi: 10.1016/s0198-8859(02)00440-8

18. Carulli L., Canedi I., Rondinella S., et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphismis associated with nonalcoholic steatohepatitis. Dig. Liver Dis. 2009;41(11):823-828. doi: 10.1016/j.dld.2009.03.005

19. Giannitrapani L., Soresi M., Balasus D., et al. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol. 2013; 19(16):2449-2455. doi: 10.3748/wjg.v19.i16.2449

20. Albillos A., Lario М., Alvarez-Mon М. Cirrosis-associated immune distinctive features and clinical relevance. J Hepatol. 2014;61(6): 1385-1396. doi: 10.1016/j.jhep.2014.08.010